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Identity 
Other names: MDA-9, ST1, SYCL, TACIP18 
HGNC (Hugo): SDCBP 
Location: 8q12.1 
Local order: The human SDCBP gene maps on 8q12 
between the NSMAF (neutral sphingomyelinase 
activation associated factor) and the CYP7A1 
(cytochrome P450, family 7, subfamily A, polypeptide 
1) loci, which are both in the opposite orientation. 
Note 
No translocations reported. 
DNA/RNA 
Description 
The SDCBP gene is comprised of 9 exons, spanning 
2,96 kb on chromosome 8q12. 
The SDCBP promoter region has not been functionally 
explored, although two studies (Lin et al., 1998; Stier et 
al., 2000) describe SDCBP as an interferon-gamma and 
TNF-alpha inducible gene. Among predicted 
transcription factor binding sites upstream the 
transcription start site of SDCBP there are: Nf-Kapp B, 
Nf-KappaB1 and p53. 
Transcription 
Five alternatively spliced transcript variants of SDCBP, 
each comprising 9 exons, have been described. 
Protein 
Description 
SDCBP gene codes for a syntenin protein of 298 amino 
acid residues with a predicted molecular mass of 33 
kDa (Lin et al., 1998; Grootjans et al., 1997). Three 
isoforms are produced by alternative splicing: isoform 
1 (NP_001007068.1) which represents the full-length 
protein of 298 aa; isoform 2 (NP_001007069) of 292 aa 
missing residues 12-17; isoform 3 (NP_001007070) of 
297 aa missing residue 81.  
Syntenin is a scaffolding protein, endowed with several 
biological activities and involved in cancer metastases 
development (reviewed in Das et al., 2012a). The 
molecule has four domains: an N-terminal domain (aa 
1-113) with no homology to known structural motifs, 
two PDZ domains (PDZ-1 aa 114-193 and PDZ-2 aa 
198-273) and a COOH-terminal domain. The crystal 
structure of the two PDZ domains showed independent 
interaction of each domain with protein targets 
(Cierpicki et al., 2005; Kang et al., 2004). 
Postranslational modifications: syntenin can be 
phosphorylated on tyrosine (Sulka et al., 2009) and
serine residues (Rajesh et al., 2011). 
Expression 
SDCBP is expressed in fetal kidney, liver, lung and 
brain. In adult high expression is present in hearth nd 
placenta (Lin et al., 1998; Zimmermann et al., 2001).  
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SDCBP gene organization, mRNA and encoded proteins. The SDCBP gene is comprised of 9 exons and results in 5 alternatively 
spliced transcript variants (TV), which encode for three different protein isoforms (additional transcripts variants were also reported). 
Coding exons are in blue and UTRs in yellow. Transcript variants 1 and 2 differ only in their 5' UTR regions and encode for the same full-
length protein, named isoform 1. Transcript variant 3 derives from the usage of an alternative in frame splice-site in the 5' coding region 
(exon 1) and encodes for the protein isoform 2, lacking 6 residues. Transcript variant 4 uses an alternative splice site in exon 5 resulting 
in a protein isoform lacking one residue (isoform 3). Transcript variant 5 differs from variant 4 in the 5' UTR and encodes for the same 
protein isoform 3. Protein isoform 2 and 3 partial aa sequencies that differ from isoform 1 are in red characters. 
 
It is also expressed in several human tumor cell lines. 
Several types of tumors express high levels of SDCBP 
such as gastric, colon and breast carcinomas (Koo et 
al., 2002), cutaneous (Helmke et al., 2004) and uveal 
melanoma (Gangemi et al., 2012). 
Localisation 
SDCBP protein is localized to adherens junctions, focal 
adhesion plaques, inner side of the cell membrane, 
cytoplasm, endoplasmic reticulum, cytoskeleton 
(Zimmermann et al., 2001), nucleus (Gangemi et al., 
2012) and melanosomes (Basrur et al., 2003). It is also
present in cell-released exosomes (Baietti et al., 2012). 
Function 
SDCBP was identified as melanoma differentiation-
associated gene (MDA)-9 (Lin et al., 1998). The same 
gene was independently cloned and named syntenin, by 
yeast two hybrid screening. Syntenin interacts through 
its PDZ domains with the heparan-sulfates syndecans, 
which are involved in molecular recognition, signali g, 
and cell trafficking (Grootjans et al., 1997). Through its 
binding with syndecans and PIP2, syntenin mediates 
syndecan recycling through endosomal compartments 
(Zimmermann et al., 2002).  
This process modulates the surface availability of 
growth factor receptors such as FGFR, which follows 
syndecan in the recycling pathway (Zimmermann et al., 
2005). Syntenin binds the C-terminal domain of the 
pro-transforming growth factor α (proTGFα) 
(Fernández-Larrea et al., 1999) and to the Delta1 ligand 
of Notch (Estrach et al., 2007), tethering them to the
cell surface.  
In addition, syntenin directly interacts with the C-
terminal of Frizzled 7 and supports non-canonical Wnt 
signaling (Wawrzak et al., 2009). 
Syntenin binds to the cytoplasmic tail of the tetrasp nin 
CD63 at the plasma membrane and is therefore part of 
the tetraspanin-enriched microdomains (Latysheva et 
al., 2006).  
The over-expression of syntenin can limit 
internalization of CD63, suggesting a role for syntenin 
as a regulator of endocytosis. 
Syntenin is involved in the establishment and 
maintenance of synaptic structures through its 
interaction with several adhesion molecules, such as 
neurofascin (Koroll et al., 2001).  
Presynaptic development also depends upon the 
interaction of the syntenin PDZ domains with ephrin-
B1 and ephrin-B2 (McClelland et al., 2009).  






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(4)  242 
 
Syntenin protein-protein interactions. Syntenin is an adaptor protein, which interacts with multiple proteins and has several 
intracellular functions. 
 
SDCBP participates in the formation and maturation of 
synapses and colocalizes with Glutamate receptors at 
growth cones (Hirbec et al., 2005). Outgrowth of 
developing axon is also regulated by syntenin, which 
provides a scaffold for the serine/threonine kinase 
Unc51.1 and for Rab5 GTPase (Tomoda et al., 2004). 
Syntenin participates in B cell development and 
differentiation by interacting with interleukin-5 (IL-5) 
receptor α and the transcription factor Sox4 and 
mediates IL-5-induced Sox4 activation (Geijsen et al., 
2001). Proteosomal degradation of Sox4 is prevented 
by the binding of its c terminal domain with SDCBP, 
which contributes to its localization into the nucleus 
(Beekman et al., 2012). 
Syntenin mediates the generation of functional 
asymmetry in T cells during the cellular response to 
polarized extracellular cues, through the generation of 
polarized actin structures (Sala-Valdés et al., 2012). 
Syntenin interacts with Ubiquitin through is C- and N-
terminal regions and facilitates the recruitment of 
ubiquitinated proteins to its transmembrane partners. 
The process is facilitated by syntenin dimerization and 
is inhibited by phosphorylation of its serin in the N 
terminal domain mediated by Ulk1 (Rajesh et al., 
2011). 
Syntenin has a key role in exosome formation through 
the binding of syndecan 1, syndecan 2, syndecan 3, 
syndecan 4 with the PDZ domains and ALIX with the 
N-terminal domain (Baietti et al., 2012). 
Homology 
The SDCBP gene is conserved in chimpanzee, Rhesus 
monkey, dog, cow, mouse, rat, chicken, zebrafish, and 
mosquito (NCBI). 
Paralog: SDCBP2. 
SDCBP is highly related to SDCBP2 at the amino acid 
level (70% over the PDZ domains) and in the domains 
organization (Koroll et al., 2001). 
Mutations 
Note 
Not yet described. Genetic polymorphisms of SDCBP 
(561 SNPs) have been reported (NCBI) but their 




SDCBP gene was identified as an interferon-inducible 
gene in melanoma cells (Lin et al., 1998). A subtractory 
library approach of candidate metastasis genes 
identified the syntenin gene, which was overexpressed 
in cutaneous melanoma specimens relative to 
melanocytic nevi (Helmke et al., 2004). Altering 
syntenin expression by gene transduction modulates the 
metastatic ability of human melanoma cells (Boukerch  
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et al., 2005). Syntenin over-expression increased 
phosphorylation of focal adhesion kinase, c-Jun-NH2-
kinase, p38, and nuclear factor-kappaB (NF-kappaB) in 
human melanoma cells. As a consequence tumor cell 
growth and motility are enhanced. The induction of 
membrane-type matrix metalloproteinase (MMP)-1 and 
MMP-2 promotes extracellular matrix invasion 
(Boukerche et al., 2007). Syntenin binds c-Src and 
mediates the formation of an active FAK/c-Src 
complex, increasing melanoma cell invasive properties 
(Boukerche et al., 2008). In addition, src kinase 
activation is required for syntenin-mediated activation 
of NF-kappaB (Boukerche et al., 2010). Further studies 
indicated that syntenin acts as a molecular adaptor 
linking PKCalpha and FAK activation during human 
breast cancer and melanoma cell adhesion to 
fibronectin (Hwangbo et al., 2010). 
The Raf kinase inhibitor RKIP, is downregulated in 
metastatic melanoma cells. The study of melanoma 
arrays and cell lines showed an inverse relationship 
between syntenin and RKIP expression during 
melanoma progression. Syntenin transcriptionally 
downregulated RKIP and also physically interacted 
with RKIP protein. Ectopic RKIP expression in 
melanoma cells inhibited syntenin signaling, cell 
invasion and growth and in vivo dissemination of 
melanoma cells. Therefore RKIP acts as an inhibitor of 






Uveal melanoma is a rare tumor of the eye, distinct 
from cutaneous melanoma on the basis of genetic 
alterations and clinical behavior. High expression of 
SDCBP gene correlated with metastatic progression in 
three gene expression profile datasets of primary uveal 
melanomas. High expression of syntenin protein in 
primary tumors was also related to metastatic 
recurrence. Syntenin was aslo highly expressed in liver
metastases from patients and from xenografted mice. 
Silencing of syntenin inhibited uveal melanoma cell 
migration and hepatocyte growth factor (HGF)-
triggered invasion, activation of FAK, AKT and Src. 
Conversely syntenin overexpression mediated opposite 
effects (Gangemi et al., 2012). 
Disease 
Metastatic uveal melanoma. 
Gastric and breast cancers 
Note 
The expression level of syntenin was related with 
invasive potential in human breast and gastric cancer 
cells in vitro. Syntenin gene was highly expressed in 
gastric cancer tissues. Syntenin overexpression in 
human gastric or breast cancer cells increased their
migration in vitro and induced pseudopodia formation 
on collagen I. Mutation studies suggested that the 
PDZ2 domain of syntenin is involved in the stimulatory 
effect on cell migration (Koo et al., 2002). 
Colon cancer 
Note 
The proteoglycan syndecan-2 is involved in 
tumorigenicity of colon cancer cells. Syndecan-2-
induced migration requires the EFYA motif in its C-
terminal region as its deletion inhibited cell migration 
and interaction with syntenin. In addition, 
overexpression of syntenin in colon cancer cells 
enhanced their migratory capacity, while syntenin 
silencing had opposite effects. Syntenin interaction 
with syndecan-2 mediates Rac activation, and colon 
cancer cell migration (Lee et al., 2011). 
HIV infection 
Note 
Syntenin is recruited to the plasma membrane during 
HIV-1 attachment and associates with CD4. Syntenin 
overexpression inhibits HIV-1 production and HIV-
mediated cell fusion, while syntenin depletion increases 
HIV-1 entry, suggesting a regulatory role of syntenin i  
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